MOLN Molecular Partners: Multiplikator nilai perusahaan marang pendapatan

Molecular Partners AG (MOLN) - logo korporat

Molecular Partners AG (MOLN) relies on Swiss laboratories and global CDMO partners to minimize risks. The EV/Sales history in the GURU.Markets analytics includes this chart, where the current mark is 0.00, reflecting the market value to revenue ratio. Stability in R&D personnel supports the development of DARPin therapy, while payments from AbbVie and new clinical successes stimulate business growth.

Molecular Partners - Rasio nilai perusahaan marang pendapatan MOLN (periode 23.11.2025 - 20.11.2026)

MOLN (Molecular Partners Ltd): rincian analitis lan laporan miturut indikator

Analisis wiwitan perusahaan:MOLN, molecularpartners.com
Produk asli Molecular Partners

The EV/Sales metric determines the total value of the business, including debt, relative to generated revenue. For Molecular Partners AG (MOLN), this calculation is complicated by the absence of regular sales and a reliance on one-off partnership payments. Analyzing this chart of the company's enterprise value to revenue ratio, an investor sees the volatility of market expectations. This price action reflects a speculative valuation of the oncology platforms' prospects. High values here signal inflated expectations amid low operational stability.